MOUNTAIN VIEW, Calif., Sept. 27, 2011 /PRNewswire/ -- AccessClosure, Inc., a leading manufacturer of extravascular closure devices, announced today the shipment of its one millionth Mynx unit. The Mynx Vascular Closure Device received its FDA approval in May 2007, following with its full commercial launch in September 2007. Physician feedback attributes the achievement of this monumental milestone to the fact that the Mynx sealant is extravascular, bio-inert and non-thrombogenic, while leaving nothing behind intra-arterially.
"It is gratifying that one million patients will have benefited from the Mynx device just four and a half years after introduction to the marketplace. Excellent clinical efficacy and safety have been demonstrated with the Mynx device, and both physicians and their patients greatly appreciate the device's comfort profile," said Gregory D. Casciaro, President and CEO of AccessClosure, Inc.
In addition, increased patient comfort continues to resonate with both physicians and nurses as one of their top selection criteria in choosing the Mynx as their preferred extravascular closure device. Results from a recent prospective, randomized study indicate a significant reduction in pain with the Mynx Vascular Closure Device when compared to competitive devices. The study found that 88% of patients find closure to be the most painful part of the procedure when a competitive device was used compared to 34% of patients when the Mynx device was used.
"Today is a monumental occasion for AccessClosure, Inc.," said Fred Khosravi, Chairman of the Board and co-founder of AccessClosure. "Vascular closure has been one of the most competitive segments in the medical device marketplace, controlled by a handful of competitors. Not since the Mynx received its approval four years ago has an
|SOURCE AccessClosure, Inc.|
Copyright©2010 PR Newswire.
All rights reserved